Kaplan-Meier survival curve analysis in IGHV3-21 CLL patients. (A) Comparison of survival probabilities in IGHV3-21 patients (22 patients), patients with M IGHV gene configuration (at least 2%, 176 patients), and patients with UM IGHV gene configuration (less than 2%, 103 patients). (B) Comparison of survival probabilities in homHCDR3–IGHV3-21 CLLs (15 patients), M cases (180 patients), and UM cases (106 patients). (C) Kaplan-Meier curves comparing survivals in M IGHV3-21 cases (14 patients) versus M CLLs (176 patients). (D) Kaplan-Meier curves comparing survivals in M homHCDR3–IGHV3-21 CLLs (10 patients) versus all M CLLs (180 patients). Reported P values refer to the log-rank test.